Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment 0 24.06.2019 20:15 CNBC Shares of Bristol-Myers Squibb plunged Monday after announcing that the target closing date for the proposed acquisition of Celgene has been pushed back and that the deal will include a divestiture of Otezla, a psoriasis drug. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
